|
pubmed:abstractText |
In this issue of Cell Stem Stell, Bleau et al. report that activity of the drug transporter ABCG2 defines a tumorigenic stem-like side population (SP) isolated from glioma. Surprisingly, temozolomide, the first-line chemotherapeutic used for treatment of glioma, increased this side population, and even more so when PTEN was deleted.
|
|
pubmed:affiliation |
Department of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA. anders.persson@ucsf.edu
|
